Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. [electronic resource]
Producer: 20080312Description: 1102-7 p. digitalISSN:- 1078-8956
- Animals
- Antipsychotic Agents -- therapeutic use
- Benzodiazepines -- therapeutic use
- Bridged Bicyclo Compounds, Heterocyclic -- therapeutic use
- Cyclic S-Oxides -- therapeutic use
- Disease Models, Animal
- Double-Blind Method
- Humans
- Olanzapine
- Placebos
- Receptors, Metabotropic Glutamate -- drug effects
- Schizophrenia -- drug therapy
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.